Skip to main content

Adcetris (brentuximab) Disease Interactions

There are 8 disease interactions with Adcetris (brentuximab):

Major

Brentuximab vedotin (applies to Adcetris) hepatotoxicity

Major Potential Hazard, Moderate plausibility. Applicable conditions: Liver Disease

The use of brentuximab vedotin should be avoided in patients with moderate or severe hepatic impairment. Serious cases of hepatotoxicities have occurred in patients receiving this agent. Patients with preexisting liver disease, and those with elevated baseline liver enzymes may be at an increased risk. Monitor liver enzymes and bilirubin. Patients experiencing new, worsening, or recurrent hepatotoxicity may require a delay, change in dose, or discontinuation of therapy.

Major

Brentuximab vedotin (applies to Adcetris) infections

Major Potential Hazard, Moderate plausibility. Applicable conditions: Infection - Bacterial/Fungal/Protozoal/Viral

Serious infections, including opportunistic infections have been reported with the use of brentuximab vedotin. Monitor patients closely for the development of any infection during treatment with this agent. JC virus infection resulting in progressive multifocal leukoencephalopathy (PML) has been reported in patients treated with this agent. A diagnosis of PML should be considered in any patient presenting with new-onset of neurological manifestations and a consultation with a neurologist is recommended. Hold therapy for any suspected case of PML and discontinue if a diagnosis of PML is confirmed.

Major

Brentuximab vedotin (applies to Adcetris) renal impairment

Major Potential Hazard, Moderate plausibility. Applicable conditions: Renal Dysfunction

The frequency of adverse reactions, including fatalities are increased in patients with severe renal impairment. It is recommended to avoid the use of this agent in patients with severe renal impairment.

Major

Monoclonal antibodies (applies to Adcetris) tumor lysis syndrome

Major Potential Hazard, Moderate plausibility.

Tumor lysis syndrome (TLS) has occurred in patients receiving certain monoclonal antibodies. Patients with high tumor burden and those with high circulating lymphocyte counts of greater than 25 X 10^9/L have a higher risk of developing TLS. Consider tumor lysis prophylaxis prior to the infusion with anti-hyperuricemics and hydration beginning 12 to 24 hours prior to infusion. It is recommended to correct electrolytes abnormalities, and monitor renal function in patients who develop TLS. Monitor for signs and symptoms of TLS and temporary interruption or discontinuation of therapy might be required.

Moderate

Brentuximab vedotin (applies to Adcetris) hematologic toxicities

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Neutropenia, Thrombocytopenia, Anemia

Hematological toxicities, including prolonged severe neutropenia, thrombocytopenia or anemia can occur with the use of brentuximab vedotin. It is recommended to monitor patients for fever and if appropriate, dose delays, reduction, or discontinuation of treatment should be considered.

Moderate

Brentuximab vedotin (applies to Adcetris) peripheral neuropathy

Moderate Potential Hazard, Moderate plausibility.

Peripheral neuropathy, predominantly sensory neuropathy has occurred in patients treated with brentuximab vedotin. It is recommended to monitor patients for symptoms of neuropathy and in those experiencing new or worsening peripheral neuropathy. It is recommended to delay, or change dosage, or discontinue treatment as appropriate.

Moderate

Brentuximab vedotin (applies to Adcetris) pulmonary toxicity

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Pulmonary Impairment

Cases of noninfectious pulmonary toxicity including pneumonitis, interstitial lung disease, and acute respiratory distress syndrome (ARDS), some with fatal outcomes, have been reported with the use of brentuximab vedotin. Care should be taken when using this agent in patients at risk of pulmonary events. Hold dose in the event of new or worsening of pulmonary complications until symptoms improve.

Moderate

Brentuximab vedotin -GI events

Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Obstruction

Cases of fatal and serious gastrointestinal complication have been reported with the use of brentuximab vedotin. Care should be taken when using this agent in patients with a history of gastrointestinal complications, as its use can increase the risk of perforation. Closely monitor for new or worsening of GI symptoms and treat according to clinical practices.

Adcetris (brentuximab) drug interactions

There are 521 drug interactions with Adcetris (brentuximab)

Adcetris (brentuximab) alcohol/food interactions

There is 1 alcohol/food interaction with Adcetris (brentuximab)

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.